The Finkelstein-Schoenfeld Test : A Note on Some Overlooked Issues Concerning Power
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply..
In this note, we express our viewpoint regarding power considerations, via simulation studies, in clinical study design using hierarchical composite endpoint and Finkelstein-Schoenfeld test.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Therapeutic innovation & regulatory science - 58(2024), 3 vom: 05. Apr., Seite 465-472 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Rong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43441-023-00608-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36805991X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36805991X | ||
| 003 | DE-627 | ||
| 005 | 20240426233638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43441-023-00608-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM36805991X | ||
| 035 | |a (NLM)38316728 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Rong |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Finkelstein-Schoenfeld Test |b A Note on Some Overlooked Issues Concerning Power |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. | ||
| 520 | |a In this note, we express our viewpoint regarding power considerations, via simulation studies, in clinical study design using hierarchical composite endpoint and Finkelstein-Schoenfeld test | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Composite endpoint | |
| 650 | 4 | |a Correlation | |
| 650 | 4 | |a Finkelstein–Schoenfeld | |
| 650 | 4 | |a Study power | |
| 650 | 4 | |a Time-to-event | |
| 700 | 1 | |a Chen, Wei-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic innovation & regulatory science |d 2013 |g 58(2024), 3 vom: 05. Apr., Seite 465-472 |w (DE-627)NLM243752342 |x 2168-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2024 |g number:3 |g day:05 |g month:04 |g pages:465-472 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43441-023-00608-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2024 |e 3 |b 05 |c 04 |h 465-472 | ||